Opus Genetics, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
Opus Genetics, Inc. (IRD) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $14.77 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-03-12
- Opus Genetics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was $11.47M.
- Opus Genetics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was -$3.34M.
- Opus Genetics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was -$3.65M.
- Opus Genetics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2022-03-31 was -$5.29M.
- Opus Genetics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was $14.77M.
- Opus Genetics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was -$20.18M, a 356.51% decline from fiscal 2023.
- Opus Genetics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was $7.87M, a 56.54% decline from fiscal 2022.
- Opus Genetics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was $18.10M, a 122.50% increase from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | $14.77M 10-K · filed 2026-03-12 | |||||||
| 2025-09-30 | $494.00K 10-Q · filed 2025-11-12 | |||||||
| 2025-06-30 | $2.11M 10-Q · filed 2025-08-13 | |||||||
| 2025-03-31 | $11.47M 10-Q · filed 2025-05-15 | |||||||
| 2024-12-31 | -$20.18M 10-K · filed 2026-03-12 | |||||||
| 2024-09-30 | -$13.87M 10-Q · filed 2025-11-12 | |||||||
| 2024-06-30 | -$9.09M 10-Q · filed 2025-08-13 | |||||||
| 2024-03-31 | -$3.34M 10-Q · filed 2025-05-15 | |||||||
| 2023-12-31 | $7.87M 10-K · filed 2025-03-31 | |||||||
| 2023-09-30 | -$284.00K 10-Q · filed 2024-11-12 | |||||||
| 2023-06-30 | -$2.66M 10-Q · filed 2024-08-13 | |||||||
| 2023-03-31 | -$3.65M 10-Q · filed 2024-05-10 | |||||||
| 2022-12-31 | $18.10M 10-K · filed 2024-03-08 | |||||||
| 2022-09-30 | -$10.68M 10-Q · filed 2023-11-13 | |||||||
| 2022-06-30 | -$7.51M 10-Q · filed 2023-08-11 | |||||||
| 2022-03-31 | -$5.29M 10-Q · filed 2023-05-15 | |||||||
| 2021-12-31 | $8.13M 10-K · filed 2023-03-30 | |||||||
| 2021-09-30 | $5.85M 10-Q · filed 2022-11-04 | |||||||
| 2021-06-30 | $7.83M 10-Q · filed 2022-08-12 | |||||||
| 2021-03-31 | -$5.80M 10-Q · filed 2022-05-13 | |||||||
| 2020-12-31 | $14.86M 10-K · filed 2022-03-24 | |||||||
| 2020-09-30 | -$815.00K 10-Q · filed 2021-11-12 | -$1.14M 10-Q · filed 2020-10-29 | ||||||
| 2020-06-30 | -$683.00K 10-Q · filed 2021-08-12 | -$10.60K 10-Q · filed 2020-08-14 | ||||||
| 2020-03-31 | -$284.00K 10-Q · filed 2021-05-07 | $1.78M 10-Q · filed 2020-05-07 | ||||||
| 2019-12-31 | $1.09M 10-K · filed 2021-03-11 | $475.25K 10-K · filed 2020-02-21 | ||||||
| 2019-09-30 | -$812.20K 10-Q · filed 2020-10-29 | |||||||
| 2019-06-30 | -$1.43M 10-Q · filed 2020-08-14 | |||||||
| 2019-03-31 | -$2.62M 10-Q · filed 2020-05-07 | |||||||
| 2018-12-31 | -$154.85K 10-K · filed 2020-02-21 | |||||||
| 2018-09-30 | -$4.31M 10-Q · filed 2019-11-06 | |||||||
| 2018-06-30 | -$3.80M 10-Q · filed 2019-08-07 | |||||||
| 2018-03-31 | -$2.60M 10-Q · filed 2019-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |